News Menu

One experiment: Capturing a drug in its binding pocket

黑料吃瓜资源

This computer-generated 3-D image, from Erkan Karakas, Ph.D., a postdoctoral researcher in the lab of CSHL Associate Professor Hiro Furukawa, reveals in exquisite detail the shape of a previously elusive binding pocket for a drug that may help treat neurodegenerative diseases including Alzheimer鈥檚 and Parkinson鈥檚, as well as brain damage from stroke.

The neuroprotective drug is called ifenprodil. It鈥檚 the green 鈥渟tick鈥 you can half-glimpse through a tiny opening in the structure in which it is embedded (loops and ribbons represent amino acids forming the structure). The binding pocket is like a keyhole, where only molecules of a very particular shape and electrical charge can fit. This view shows how ifenprodil binds within one pocket in one portion of a type of NMDA receptor. Found throughout the human brain, NMDA receptors are tiny pores whose opening and closing helps regulate signals—excitatory nerve impulses—between cells carried by the neurotransmitter glutamate.

This rendering of the amino terminal domain (ATD) of an NMDA receptor has significance for drug developers. 鈥淲hen you can see where, how, and how well a candidate drug fits in a binding pocket, you can begin to tweak it to make sure it binds only there and not at other receptors in the body, where it can cause harmful side effects,鈥 Karakas explains. Two years of work went into this solution of the structure, using a method called x-ray crystallography.

The team deduced that movement of the lower (yellow) of the two linked protein assemblies on the ATD鈥檚 right side (cyan and yellow, comprising the GluN2B subunit) enables ifenprodil to enter and exit the tiny pocket. One experiment in the series proved that binding at this 鈥渁llosteric鈥 site in the ATD shuts down the larger NMDA receptor—important because NMDA overactivity is linked with neurodegeneration. The way is now open for development of an ifenprodil-like drug that binds even more exclusively at this site, minimizing side effects.

Written by: Peter Tarr, Senior Science Writer | [email protected] | 516-367-8455

Stay informed

Sign up for our newsletter to get the latest discoveries, upcoming events, videos, podcasts, and a news roundup delivered straight to your inbox every month.

  Newsletter Signup

About

Hiro Furukawa

Hiro Furukawa

Professor
Cancer Center Member
Ph.D., The University of Tokyo, 2001

Tags